ipid profiles of HIV-infected patients with dyslipidemia after switching from efavirenz to dolutegravir

• Conditions: HIVDyslipidemia; HIV; Dyslipidemia

• Registration Number: TCTR20221118002
• Lead Sponsor: Khon Kaen university

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-11-18
• Study Completion: 2023-02-02
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Unknown
• Sex: All
• Target Recruitment: 64

Inclusion Criteria

This is a prospective, open-label, cohort study in HIV-1 infected adults aged more than18 years who have undergone at least six months of EFV-based therapy, have HIV-1 RNA levels less than 50 copies/mL for more than 6 months before switching, and are diagnosed with dyslipidemia or have risk factors for atherosclerosis cardiovascular disease (ASCVD) based on modified National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III guidelines.

Exclusion Criteria

Exclusion criteria are pregnancy or breastfeeding, active opportunistic infections, or taking metformin more than 1,000 mg/day, rifampicin, St. john's wort, antiarrhythmic drugs (e.g., dofetilide, pilsicainide), antiepileptic drugs (e.g., carbamazepine, oxcarbazepine, phenytoin, phenobarbital), or medications or supplements containing polyvalent cations (e.g., magnesium, aluminum, cation-containing antacids or laxatives, sucralfate, buffered medications).

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
ipid profiles 24 weeks mg/dL,Weight 24 weeks Kg,Waist 24 weeks cm

Secondary Outcome Measures

Name	Time	Method
ipid profiles 12 weeks mg/dL,Weight 12 weeks Kg,Waist 12 weeks cm